Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR

mAbs

Volumn 1, Issue 2, 2009, Pages 128-141

  Michaelson, Jennifer S ^a   Demarest, Stephen J ^a   Miller, Brian ^a   Amatucci, Aldo ^a   Snyder, William B ^a   Wu, Xiufeng ^a   Huang, Flora ^a   Phan, Samantha ^a   Gao, Sharon ^a   Doern, Adam ^a   Farrington, Graham K ^a   Lugovskoy, Alexey ^a   Joseph, Ingrid ^a   Bailly, Veronique ^a   Wang, Xin ^b   Garber, Ellen ^a   Browning, Jeff ^a   Glaser, Scott M ^a  

^a BIOGEN   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Antibody therapeutics; Bispecific antibodies; Cancer treatment; Immunoglobulins; Pharmacokinetics; Protein engineering; Protein stability; Single chain Fv; Tumor inhibition

Indexed keywords

BISPECIFIC ANTIBODY; DEATH RECEPTOR 5; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; LYMPHOTOXIN BETA RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CROSS LINKING; EPITHELIUM TUMOR; HEAVY CHAIN; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN ENGINEERING; THERMODYNAMICS; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LYMPHOTOXIN BETA RECEPTOR; MICE; MICE, SCID; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROTEIN ENGINEERING; PROTEIN STABILITY; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70449770418     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.2.7631     Document Type: Article

References (39)

1. Fischer N, Leger O. Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 2007; 74:3-14. (Pubitemid 46742313)
2. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 2003; 44:400-411 (Pubitemid 39586017)
3. Jain M, Kamal N, Batra SK. Engineering antibodies for clinical applications. Trends Biotechnol 2007; 25:307-316
4. Kontermann RE. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 2005; 26:1-9. (Pubitemid 40093233)
5. Marvin JS, Zhu Z. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 2005; 26:649-658 (Pubitemid 40806552)
6. Worn A, Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 2001; 305:989-1010. (Pubitemid 33028934)
7. Ewert S, Huber T, Honegger A, Pluckthun A. Biophysical properties of human antibody variable domains. J Mol Biol 2003; 325:531-553 (Pubitemid 36062681)
8. Ewert S, Honegger A, Pluckthun A. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods Enzymol 2004; 34:184-199 (Pubitemid 39092813)
9. Brockmann EC, Cooper M, Stromsten N, Vehniainen M, Saviranta P. Selecting for antibody scFv fragments with improved stability using phage display with denaturation under reducing conditions. J Immunol Methods 2005; 296:159-170 (Pubitemid 40174749)
10. Reiter Y, Brinkmann U, Lee B, Pastan I. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat Biotechnol 1996; 14:1239-1245 (Pubitemid 26332783)
11. Buchsbaum DJ, Zhou T, Lobuglio AF. TRAIL receptor-targeted therapy. Future Oncol 2006; 2:493-508.
12. Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, et al. Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res 2006; 66:9617-9624 (Pubitemid 44623661)
13. Rothlisberger D, Honegger A, Pluckthun A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol 2005; 347:773-789 (Pubitemid 40357919)
14. Desplancq D, King DJ, Lawson AD, Mountain A. Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3. Protein Eng 1994; 7:1027-1033 (Pubitemid 24256883)
15. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nature Rev Immunol 2007; 7:715-725 (Pubitemid 47327396)
16. Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 1997; 15:159-163 (Pubitemid 27081782)
17. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280:19665-19672 (Pubitemid 41379490)
18. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677-681 (Pubitemid 28334328)
19. Shen J, Vil MD, Jimenez X, Zhang H, Iacolina M, Mangalampalli V, et al. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. J Immunol Methods 2007; 318:65-74. (Pubitemid 46026806)
20. Asano R, Watanabe Y, Kawaguchi H, Fukazawa H, Nakanishi T, Umetsu M, et al. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J Biol Chem 2007; 282:27659-27665 (Pubitemid 47529493)
21. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-1297 (Pubitemid 350076510)
22. Glockshuber R, Malia M, Pfitzinger I, Pluckthun A. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 1990; 29:1362-1367 (Pubitemid 20063361)
23. Young NM, MacKenzie CR, Narang SA, Oomen RP, Baenziger JE. Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond. FEBS Lett 1995; 377:135-139 (Pubitemid 26015060)
24. Jung S, Honegger A, Plückthun A. Selection for improved protein stability by phage display. J Mol Biol 1999; 294:163-180
25. Krauss J, Arndt MA, Martin AC, Liu H, Rybak SM. Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment. Protein Eng 2003; 16:753-759 (Pubitemid 37442446)
26. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol and Cell Biol 2003; 23:1428-1440 (Pubitemid 36177050)
27. Gajate C, Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007; 109:711-719 (Pubitemid 46105973)
28. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234:779-815. (Pubitemid 223006096)
29. Jacobson MP, Pincus DL, Rapp CS, Day TJ, Honig B, Shaw DE, Friesner RA. A hierarchical approach to all-atom protein loop prediction. Proteins 2004; 55:351-367 (Pubitemid 38437493)
30. Canutescu AA, Shelenkov AA, Dunbrack RL Jr. A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci 2003; 12:2001-2014 (Pubitemid 37022822)
31. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. CHARMM: A program for macromolecular energy, minimization and dynamics calculations. J Comput Chem 1983; 4:187-217.
32. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of Proteins of Immunological Interest. Washington DC, USA: US Department of Health and Human Services 1991.
33. Mage MG. Preparation of Fab fragments from IgGs of different animal species. Methods Enzymol 1980; 70:142-150
34. Eldredge J, Berkowitz S, Corin AF, Day ES, Hayes D, Meier W, Strauch K, Zafari M, Tadi M, Farrington GK. Stoichiometry of LTbetaR binding to LIGHT. Biochemistry 2006; 45:10117-10128
35. Yang J, Moyana T, MacKenzie S, Xia Q, Xiang J. One hundred seventy-fold increase in excretion of an FV fragment-tumor necrosis factor alpha fusion protein (sFV/TNFalpha) from Escherichia coli caused by the synergistic effects of glycine and triton X-100. Appl Enviro Microbiol 1998; 64:2869-2874 (Pubitemid 28363154)
36. Barnett RS, Limoli KL, Huynh TB, Ople EA, Reff ME, eds. Antibody Expression and Engineering. New York NY.: Oxford University Press 1995.
37. Brezinsky SC, Chiang GG, Szilvasi A, Mohan S, Shapiro RI, MacLean A, et al. A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity. J Immunol Methods 2003; 277:141-155 (Pubitemid 36694381)
38. Kim JK, Tsen MF, Ghetie V, Ward ES. Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. Eur J Immunol 1994; 24:542-548 (Pubitemid 24076614)
39. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272:32401-32410 (Pubitemid 28011923)